- ANCHOR trial shows treatment for HSIL reduces anal cancer risk by 57%.
- Routine screening recommended for MSM and transgender women with HIV starting at age 35.
- Average incidence of anal cancer: 85 per 100,000 for MSM. 4. Serious adverse events occurred in 1.4% of the treatment group. 5. HPV type 16 implicated in most anal cancers. 6. Electrocautery ablation commonly used treatment. 7. No FDA-approved therapy specifically for HSIL.
Source: Clinical Infectious Disease
